BACHEM
LIVE

Serial Number

79281569

Owner

BACHEM HOLDING AG

Attorney

Sarah M. Robertson

Filing Date

Dec 27, 2019

Add to watchlist:

No watchlists yet
View on USPTO

BACHEM Trademark

Serial Number: 79281569 • Registration: 6748998

BACHEM is a trademark filed by BACHEM HOLDING AG on December 27, 2019. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

BACHEM HOLDING AG (10 trademarks)

HAUPTSTRASSE 144
BUBENDORF 4416 , CH

Entity Type: 03

Trademark Details

Filing Date

December 27, 2019

Registration Date

June 7, 2022

Published for Opposition

February 15, 2022

Goods & Services

Chemicals for use in industry and science; chemical preparations for scientific use; chemical preparations for use in industry; industrial chemicals; reagents for research purposes; reagents for scientific use; chemical preparations for scientific use, other than for medical or veterinary use; chemical reagents, other than for medical or veterinary use; chemicals for industry; chemical reagents for scientific use; peptides for use in industry and science; proteins for use in industry and science; oligonucleotides for use in industry and science; oligopeptides for industrial use; proteins for industrial use; proteins for use in manufacture; amino acids for industrial use; amino acids for scientific use; peptide substrates for scientific use; chemical preparations for use in the manufacture of cosmetics; peptides for use in the manufacture of cosmetics; proteins for use in the manufacture of cosmetics; oligonucleotides for use in the manufacture of cosmetics; chemical preparations for use in the production of medicines; chemical preparations for use in the manufacture of pharmaceuticals; peptides for use in the manufacture of pharmaceuticals; proteins for use in the manufacture of pharmaceuticals; oligonucleotides for use in the manufacture of pharmaceuticals; chemical reagents for use in genetic research; chemicals for use in biotechnological manufacturing processes; chemicals for use in biotechnological product development; active chemical ingredients for use in the manufacture of anti-cancer drugs; active chemical ingredients for use in the manufacture of anti-diabetes drugs; active chemical ingredients for use in the manufacture of drugs against metabolic diseases; active chemical ingredients for use in the manufacture of drugs for wound healing; active chemical ingredients for use in the manufacture of drugs against genetic diseases; active chemical ingredients for use in the manufacture of drugs against neurological diseases; amides for use in manufacture; chemical additives for use in the manufacture of cosmetics; chemical additives for use in the manufacture of medicines; chemical additives for use in the manufacture of pharmaceuticals; diagnostic preparations for scientific or research use; diagnostic preparations, other than for medical or veterinary use; diagnostic reagents for scientific or research use; diagnostic reagents, other than for medical or veterinary use; biological preparations for use in industry and science; biological preparations, other than for medical or veterinary use; adjuvants, other than for medical or veterinary purposes; biochemical catalysts; biochemical preparations for scientific use; biochemicals for in vitro and in vivo scientific use; emollients for industrial use; emollients for use in the manufacture of cosmetics; emollients for use in the manufacture of pharmaceuticals; enzyme stabilizers; enzyme substrates; phosphoproteins

Chemical reagents for medical or veterinary use; reagents for medical use; peptides for medical use; protein arrays for medical diagnostic use; oligonucleotides for medical use; amino acids for medical use; peptides for pharmaceutical use; synthetic peptides for pharmaceutical use; peptides for veterinary use; amino acids for veterinary use; diagnostic preparations for medical use; diagnostic preparations for veterinary use; biological and pharmaceutical preparations for diagnostic purposes; diagnostic test reagents for medical or veterinary use; peptides for diagnostic purposes; proteins for diagnostic purposes; oligonucleotides for diagnostic purposes; diagnostic kits containing diagnostic agents, preparations and substances for medical use; chemical preparations for the diagnosis of pregnancy; biological and chemical reagents for medical or veterinary use; biological preparations for diagnostic purposes; pharmaceutical preparations against metabolic diseases; pharmaceutical preparations for wound healing; pharmaceutical preparations against genetic diseases; pharmaceutical preparations against neurological diseases; biological reagents for medical use; biological reagents for veterinary use; adjuvants for medical use; adjuvants for veterinary use; anti-bacterial preparations for medical purposes; anti-cancer preparations; antitumor drugs; biopharmaceutical anti-tumor medicines; biopharmaceuticals for the treatment of cancer; anti-diabetic preparations; chemotherapeutics; cosmeceuticals for therapeutic or medical use, namely, medicated soap; dermatological preparations; diagnostic biomarker reagents for medical use; food supplements with cosmetic effect; dietetic preparations adapted for medical use; dietetic preparations adapted for veterinary use; drug delivery agents in the form of coatings for tablets that facilitate the delivery of pharmaceutical preparations; in vitro diagnostic preparations for medical use; medical diagnostic reagents and assays for testing of body fluids; nucleic acid sequences for medical and veterinary use; reagents for use in medical genetic testing; reagents for use in veterinary genetic testing

Scientific research; chemical research; chemical engineering; product research and development; research and development of new products for others; research and development services in the field of chemistry; research and development in the field of peptides; research and development in the field of proteins; research and development in the field of oligonucleotides; research and development services for the pharmaceutical industry; research and development services in the field of pharmaceutical preparations; research and development services in the field of biochemistry; research and development services in the field of cosmetics; research and development services in the field of diagnostic preparations; research and development services in the field of gene expression systems; research in the fields of chemistry and biology; development of methods of manufacture for peptides, proteins, oligonucleotides, pharmaceuticals, and cosmetics; development of analytic methods for developing for peptides, proteins, oligonucleotides, pharmaceuticals, and cosmetics; scientific laboratory services; chemical analysis; chemical, biochemical, biological and bacteriological research and analysis; analysis in the form of research in the field of molecular biology; conducting of scientific feasibility studies; providing information in the form of preparation of reports relating to scientific research; quality control; product testing; advisory services relating to material testing; consultancy in the field of biochemistry research; consultancy in the field of chemistry research; consultancy in the field of scientific and industrial research; consultancy relating to laboratory testing research; consulting services in the field of recombinant DNA technology research

Custom manufacture of pharmaceuticals; custom manufacture of biopharmaceuticals; custom manufacturing of peptides; custom manufacturing of proteins; custom manufacturing of oligonucleotides; processing of chemicals; processing of chemical reagents; processing of peptides; processing of proteins; processing of oligonucleotides; processing of medicinal materials; processing of biopharmaceutical materials for others; treatment of biopharmaceutical materials

Filing History

NEW REPRESENTATIVE AT IB RECEIVED
Nov 30, 2025 NREP
FINAL DECISION TRANSACTION PROCESSED BY IB
Oct 10, 2022 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Sep 19, 2022 FICS
FINAL DISPOSITION PROCESSED
Sep 19, 2022 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Sep 7, 2022 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Jun 7, 2022 NRCC
REGISTERED-PRINCIPAL REGISTER
Jun 7, 2022 R.PR
ELECTRONIC RECORD REVIEW COMPLETE
Apr 29, 2022 FIXD
ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
Apr 1, 2022 ERRR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Feb 15, 2022 NPUB
PUBLISHED FOR OPPOSITION
Feb 15, 2022 PUBO
NOTIFICATION PROCESSED BY IB
Feb 13, 2022 GPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Jan 26, 2022 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Jan 26, 2022 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jan 26, 2022 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 11, 2022 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 8, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 7, 2022 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 7, 2022 TROA
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Sep 19, 2021 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Sep 1, 2021 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Sep 1, 2021 OPNR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jul 7, 2021 GNRN
NON-FINAL ACTION E-MAILED
Jul 7, 2021 GNRT
NON-FINAL ACTION WRITTEN
Jul 7, 2021 CNRT
LIMITATION FROM THE IB - REQUEST EXAM REVIEW
May 25, 2021 LIME
NOTIFICATION OF FINAL REFUSAL EMAILED
Feb 24, 2021 GNFN
FINAL REFUSAL E-MAILED
Feb 24, 2021 GNFR
FINAL REFUSAL WRITTEN
Feb 24, 2021 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 29, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 29, 2021 CRFA
ASSIGNED TO LIE
Jan 28, 2021 ALIE
LIMITATION OF GOODS RECEIVED FROM IB
Nov 27, 2020 LIMG
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Oct 19, 2020 TROA
REFUSAL PROCESSED BY IB
May 9, 2020 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Apr 18, 2020 RFCS
REFUSAL PROCESSED BY MPU
Apr 18, 2020 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Apr 3, 2020 RFCR
APPLICATION FILING RECEIPT MAILED
Apr 3, 2020 MAFR
NON-FINAL ACTION WRITTEN
Apr 2, 2020 CNRT
ASSIGNED TO EXAMINER
Mar 30, 2020 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 30, 2020 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Mar 26, 2020 REPR